Navigation Links
Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
Date:5/14/2013

NEW YORK, May 14, 2013 /PRNewswire/ -- Intra-Cellular Therapies, Inc. ("ITI"), a biopharmaceutical company focused on the development of therapeutics for CNS disorders, is pleased to announce the appointment of Professor Sir Michael Rawlins , MD, FRCP, FMedSci, to its board of directors.  Sir Michael is an internationally respected figure in the field of drug safety, clinical effectiveness and cost effectiveness having been Chairman of the UK's National Institute for Clinical Excellence (NICE) from 1999 (at its inception) through March 2013.  NICE provides guidance to the UK's National Health Service (NHS) on whether new or existing pharmaceutical products should be made available to patients covered under the NHS and also develops clinical guidelines for patient care by NHS professionals.  Recently, Sir Michael assumed the Presidency of the UK's Royal Society of Medicine, a center for education and scholarship both in the UK and globally.  Sir Michael had a distinguished career as professor of clinical pharmacology and a general physician at the University of Newcastle upon Tyne.  He is the recipient of numerous honors over the years, such as the Hutchinson Medal in 2003, the Galen Medal in 2010, and the Prince Mahidol Award for Medicine in 2012.  He was appointed Knight Bachelor in 1999.

"We are excited to have Sir Michael Rawlins join our board," stated Sharon Mates , Ph.D., Chairman and Chief Executive Officer of Intra-Cellular Therapies.  "His expertise in the cost-effectiveness of new pharmaceuticals and other issues in health economics will be invaluable to Intra-Cellular Therapies.  I look forward to working closely with Michael as we transition our clinical programs through late-stage development and commercial approval."

"I am delighted to join the ITI Board of Directors.  It
'/>"/>

SOURCE Intra-Cellular Therapies, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. BBVA Foundation Unites the Efforts of Massachusetts General Hospital and Barcelonas Vall dHebron Hospital in Biomarker Research for Personalized Cancer Therapies
2. BioRestorative Therapies Signs Material Manufacturing Agreement With University of Utah
3. BioRestorative Therapies to Present at 7th International Conference on Cell Therapy for Cardiovascular Disease
4. BioRestorative Therapies Retains KCSA Strategic Communications as Investor Relations Counsel
5. BioRestorative Therapies Obtains $2.1 Million in 2012 Private Financing
6. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
7. BioRestorative Therapies Announces Next Generation of Stem Cell Disc Delivery Device
8. CNIO researchers describe a new target for developing anti-angiogenic and anti-tumoral therapies
9. BioRestorative Therapies Enters Into Brown Fat Research Agreement With University of Utah
10. CSL Biotherapies Awarded US Government Contract for Influenza Pandemic Preparedness and Response
11. Merrimack Pharmaceuticals To Present Preliminary Clinical Data For Novel Therapies Targeting Molecular Pathways In Advanced Cancers
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Francisco, CA (PRWEB) July 24, 2014 ... http://www.draperuniversity.com , is proud to announce that ... from 17 different countries will converge on the ... Valley for an intensive, experiential program focused on ... The highly selective school, currently running its sixth ...
(Date:7/24/2014)... As part of the long-term strategic approach, ... region during 2014 with potential global expansion. , "We ... DZS to manage our clinical trials globally and in ... R&D and President of SBI pharmaceuticals MENA, Dr. Riyadh ... a focus on utilizing eClinical software and flexible team ...
(Date:7/23/2014)... Al Khaimah, United Arab Emirates (UAE) (PRWEB) July 23, ... firm Grace Century recently announced that its ... Dr. Jim Vaught , Ph.D. to its growing Advisory ... said, “We are very pleased to have Dr. Vaught ... with the scientific depth and expertise that Provia’s management ...
(Date:7/23/2014)... Physicists Sergei Filippov (MIPT and Russian Quantum Center ... Brno, Czech Republic, and the Institute of Physics ... preserve quantum entanglement of particles passing through an ... long distances. Details are provided in an article ... (see preprint). , Quantum entangled particles are ...
Breaking Biology Technology:Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 2Summer Entrepreneurship Program Kicked Off by Draper University in Silicon Valley 3SBI Pharmaceuticals Co. Ltd. Enters into Preferred Provider Agreement with DZS Clinical Services 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 2Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 3Provia Laboratories Adds Dr. Jim Vaught, Ph.D., Former Chief of BBRB, to Advisory Board 4Scientists find way to maintain quantum entanglement in amplified signals 2Scientists find way to maintain quantum entanglement in amplified signals 3Scientists find way to maintain quantum entanglement in amplified signals 4
... enhances Microsoft Amalga Life Sciences to accelerate basic research ... June 1 Microsoft Corp. today announced that it ... to acquire certain assets of Rosetta Biosoftware, a business ... of Merck & Co. Inc. The deal allows Microsoft ...
... Move strengthens Kendle,s position as a global clinical ... , CINCINNATI, June 1 Kendle (Nasdaq: ... research organization, today announced the opening of offices ... Philippines. The new operations provide Kendle,s global ...
... , ADHD symptom control demonstrated from the first time ... , PHILADELPHIA, June 1 Shire ... global specialty biopharmaceutical company, today announced that the US ... to the prescribing information for its once-daily Attention Deficit ...
Cached Biology Technology:Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 2Microsoft Signs Agreement With Merck & Co. Inc. to Acquire Assets of Rosetta Biosoftware, Strengthening Position in Life Sciences Industry 3Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila 2Kendle Expands Asia/Pacific Operations with Opening of Offices in Kuala Lumpur, Bangkok and Manila 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 2FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 3FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 4FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 5FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 6FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD 7
(Date:7/24/2014)... soup in which life arose have been maintained in our ... Anglia. , Research published today in the Journal of ... very likely also in animals still perform ancient reactions thought ... some four billion years ago. , The primordial soup theory ... a result of the combination of metals, gases from the ...
(Date:7/24/2014)... in German . ... asthma sufferers worldwide, a further 600 million people living ... global population contending with allergic rhinitis (allergic inflammation of ... other organs and parts of the body beyond the ... the form of inflammatory bowel diseases such as colitis ...
(Date:7/24/2014)... doctors and scientists from Singapore have developed Asia,s first ... eye disease that affects the cornea called corneal stromal ... vision. , Called the POLARIS TGFBI (Transforming Growth ... to aid in the diagnosis and management of patients ... members carrying a TGFBI mutation who may also be ...
Breaking Biology News(10 mins):New drugs to combat asthma and the like 2New drugs to combat asthma and the like 3Singapore team develops Asia's first genetic test that can prevent corneal blindness 2Singapore team develops Asia's first genetic test that can prevent corneal blindness 3
... leaf has revealed the oldest known evidence of a macabre ... to turn them into zombies. The discovery has been ... Hughes, from the University of Exeter, who studies parasites that ... manner of animals are susceptible to the often deadly body ...
... from Mount Sinai School of Medicine have enhanced our ... conversion, the process in which food is converted into ... scientists gain atomic-level insight into how organisms synthesize their ... published in the August issue of PLoS Biology ...
... Mont. -- Researchers at Montana State University have ... for treating antibiotic resistant infections, fungal infections and viral ... to study such compounds. The technologies are ... The first technology involves an existing clinical drug ...
Cached Biology News:Fossil reveals 48-million-year history of zombie ants 2Mount Sinai researchers discover new mechanism behind cellular energy conversion 2Montana State University offers 6 new biomedical technologies for licensing 2Montana State University offers 6 new biomedical technologies for licensing 3Montana State University offers 6 new biomedical technologies for licensing 4
delta-like 1 homolog (Drosophila)...
ELISpot kit for human Granzyme B. Kits contain PVDF plates, capture & detection antibodies, streptavidin-ALP, BSA, Skimmed dry milk, BCIP/NTB substrate, and wash buffer...
SHEEP ANTI ECHIS OCCELATUS (VENOM)...
MOUSE ANTI RAT KAPPA/LAMBDA:HRP Immunogen: MARK-1: Rat kappa light chains (IR202 and IR968)MARL-15: Rat lambda light chains (RH58, IR31)...
Biology Products: